Chimeric Antigen Receptor Modified T Cells Targeting BCMA(The First Affiliated Hospital of Xiamen University)

N/A

Report date: 2024/09/15 20:00:04

Base Information

Drug NameChimeric Antigen Receptor Modified T Cells Targeting BCMA(The First Affiliated Hospital of Xiamen University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Source of cells > PMBC-derivedCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionT lymphocyte replacementsB-cell maturation protein modulators

TargetsB-cell maturation protein

Therapy Area/IndicationsMultiple Myeloma

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesThe First Affiliated Hospital Of Xiamen University

China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Xiamen University

Inactive CompaniesN/A

Active IndicationsMultiple Myeloma

Inactive IndicationsN/A

Other Information

ATC CodeN/A